HUMA Humacyte Inc
Price (delayed)
$1.46
Market cap
$183.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.34
Enterprise value
$192.36M
Highlights
The company's equity has shrunk by 125% QoQ
HUMA's net income has dropped by 71% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of HUMA
Market
Valuations
Earnings
Shares outstanding
125.86M
Market cap
$183.75M
Enterprise value
$192.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$112.49M
Net income
-$152.87M
EBIT
-$144.37M
EBITDA
-$137.1M
Free cash flow
-$92.26M
Per share
Balance sheet
Liquidity
EPS
-$1.34
EPS diluted
-$1.34
Free cash flow per share
-$0.77
Book value per share
-$0.53
Revenue per share
$0
TBVPS
$0.96
Total assets
$114.76M
Total liabilities
$178.49M
Debt
$79.38M
Equity
-$63.72M
Working capital
$2.06M
Debt to equity
-1.25
Current ratio
1.1
Quick ratio
3.38
Net debt/EBITDA
-0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-112.7%
Return on equity
N/A
Return on invested capital
-143.5%
Return on capital employed
-153.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HUMA stock price
How has the Humacyte stock price performed over time
Intraday
-2.01%
1 week
-27%
1 month
-57.06%
1 year
-50.84%
YTD
-71.09%
QTD
-14.37%
Financial performance
How have Humacyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$112.49M
Net income
-$152.87M
Gross margin
N/A
Net margin
N/A
HUMA's net income has dropped by 71% year-on-year and by 9% since the previous quarter
HUMA's operating income is down by 19% year-on-year and by 5% since the previous quarter
Growth
What is Humacyte's growth rate over time
Valuation
What is Humacyte stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
HUMA's EPS has dropped by 54% year-on-year and by 6% since the previous quarter
The company's equity has shrunk by 125% QoQ
Efficiency
How efficient is Humacyte business performance
Humacyte's return on assets has shrunk by 122% YoY and by 16% QoQ
HUMA's return on invested capital has dropped by 54% year-on-year and by 6% since the previous quarter
Dividends
What is HUMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HUMA.
Financial health
How did Humacyte financials performed over time
HUMA's total assets is 36% lower than its total liabilities
HUMA's current ratio has plunged by 84% YoY and by 80% from the previous quarter
Humacyte's total liabilities has surged by 59% YoY and by 7% QoQ
The debt to equity has dropped by 182% year-on-year but it has soared by 55% since the previous quarter
The company's equity has shrunk by 125% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.